Head-to-head evidence
Olanzapine (Zyprexa) vs Risperidone (Risvan)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Olanzapine (Zyprexa)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00712686 · Phase 3 · completed
The study was a large randomized, double-blind, active-controlled comparison of aripiprazole and olanzapine, with clinical outcomes including PANSS symptom scores. Because the registry does not report whether either primary endpoint was met, the treatment comparison cannot be judged as positive, negative, or mixed.
Next expected readout: February 2027 · NCT03781115 (registry estimate)
Risperidone (Risvan)
Marketed by Laboratorios Farmacéuticos Rovi, S.A.
NCT03160521 · Phase 3 · completed
The study randomized 438 participants to two risperidone doses or placebo under triple masking, with 390 participants included in the reported primary efficacy analysis. The clinical primary endpoint was the change in PANSS total score, reported as -24.6 and -24.7 points with risperidone versus -11.0 with placebo, but statistical significance for this primary comparison is not stated, so the result remains unclear.
Next expected readout: December 2027 · NCT07047651 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olanzapine (Zyprexa)'s landscape · Risperidone (Risvan)'s landscape